The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
The Association between Adherence to Levodopa/Carbidopa/Entacapone Therapy and Healthcare Utilization and Costs among Patients with Parkinsonʼs Disease: A Retrospective Claims-Based Analysis
Abstract
Background Suboptimal adherence to long-term therapies is common and may potentially have adverse consequences on patient outcomes and healthcare costs. Objective To assess the association between adherence to levodopa/carbidopa/entacapone therapy and healthcare utilization and costs in patients with Parkinson's disease. Methods A retrospective historical cohort study, conducted in the US, using a health insurance claims database, with data spanning from 1 January 2000 to 31 December 2005. Subjects included patients with Parkinson's disease who were treated with levodopa (L), carbidopa (C) and entacapone (E) either as separate tablets (LC + E) or as a single-tablet formulation (LCE). The association between satisfactory adherence (defined as 'proportion of days covered' for LCE or LC + E during 1-year follow-up ≥80%) and healthcare utilization and costs was examined using multivariate regression to control for pretreatment adherence to LC and other patient characteristics. Results Compared with unsatisfactory adherence (n = 598), satisfactory adherence (n = 617) was associated with 39% fewer Parkinson's disease-related hospitalizations (95% CI 20, 54; p Conclusions Better adherence to levodopa/carbidopa/entacapone therapy is associated with lower healthcare utilization and costs. Non-adherence to LCE is associated with a greater increase in costs than non-adherence to LC + E. Efforts should be made to ensure adherence to both therapies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“One study additionally reported the adjusted cost, estimating that $10 290 could be attributed to medication non-adherence annually.37”
From Economic impact of medication non-adherence by disease groups: a systematic review (2018) · cites this paper as [37]
Citations
Cites
(2005) · Statistics for Biology and Health · doi:10.1007/0-387-27255-0_9 · Cited by 20,133
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
DEYO, R. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90133-8 · Cited by 10,452 · cited 1×
“Medical claims during the preindex period were scanned to identify patients with a variety of co-morbid conditions (ICD-9CM codes used to identify these conditions are provided in table I) and the Deyo version of the Charlson Comorbidity Index was also calculated for each patient.([13,14]) The numbers of prescriptions…”
MethodOsterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
Generalized Linear Models (2nd ed.).
Therneau, T. M., McCullagh, P., & Nelder, J. A. (1993) · Journal of the American Statistical Association · doi:10.2307/2290358 · Cited by 4,907
National Center for Health Statistics ( NCHS )
Feinleib, M. (2005) · Encyclopedia of Biostatistics · doi:10.1002/0470011815.b2a16042 · Cited by 1,574
A Checklist for Medication Compliance and Persistence Studies Using Retrospective Databases
Peterson, A. M., Nau, D. P., Cramer, J. A., Benner, J., Gwadry-Sridhar, F., & Nichol, M. (2007) · Value in Health · doi:10.1111/j.1524-4733.2006.00139.x · Cited by 633
Olanow, C. W., Obeso, J. A., & Stocchi, F. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70521-x · Cited by 547
Choo, P. W., Rand, C. S., Inui, T. S., Lee, M.-L. T., Cain, E., Cordeiro-Breault, M., Canning, C., & Platt, R. (1999) · Medical Care · doi:10.1097/00005650-199909000-00002 · Cited by 546
Steiner, J. F., Koepsell, T. D., Fihn, S. D., & Inui, T. S. (1988) · Medical Care · doi:10.1097/00005650-198808000-00007 · Cited by 458
Suboptimal medication adherence in Parkinson's disease
Grosset, K. A., Bone, I., & Grosset, D. G. (2005) · Movement Disorders · doi:10.1002/mds.20602 · Cited by 205
Research works printed but not linked: 2
- Farley, 2006, Am J Manag Care, 12, 110
- Connor, 2004, Bull World Health Org, 82, 935
Cited by
Economic impact of medication non-adherence by disease groups: a systematic review
Cutler, R. L., Fernandez-Llimos, F., Frommer, M., Benrimoj, C., & Garcia-Cardenas, V. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-016982 · Cited by 900
Asymmetric Synthesis of l -Carbidopa Based on a Highly Enantioselective α-Amination
Pericas, À., Shafir, A., & Vallribera, A. (2013) · Organic Letters · doi:10.1021/ol400136y · Cited by 34
A systematic review of interventions to reduce hospitalisation in Parkinson's disease
Muzerengi, S., Herd, C. P., Rick, C., & Clarke, C. E. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.01.011 · Cited by 32
Reichmann, H., & Emre, M. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.203 · Cited by 25
Practical pearls to improve the efficacy and tolerability of levodopa in Parkinson’s disease
Lenka, A., Maria, G. D., Lamotte, G. J., Bahroo, L. B., & Jankovic, J. J. (2022) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2022.2091436 · Cited by 21
Metadata
- Authors
- Delea, T. E., Thomas, S. K., & Hagiwara, M.
- Affiliations
- Policy Analysis (United States) (US)
- Venue
- CNS Drugs
- Published
- 2011-01
- Volume
- 25
- Issue
- 1
- Pages
- 53-66
- ISSN
- 1172-7047 (ISSN-L)
- OpenAlex
- W66124219
- Cited by
- 28
- References
- 20
- Citations by year
- 2025: 1 · 2024: 5 · 2023: 2 · 2022: 2 · 2021: 3 · 2020: 2 · 2018: 1 · 2017: 3 · 2016: 2 · 2014: 1 · 2013: 5 · 2012: 1
- FWCI
- 1.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- CNS Drugs (publishedVersion)
- PubMed (publishedVersion)
- Funders
- School of Medicine, Duke University
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Healthcare Policy and Management
- Keywords
- Parkinson's disease, medication adherence, levodopa/carbidopa/entacapone, entacapone, carbidopa, levodopa, health care utilization, health care costs, hospitalization, proportion of days covered
- MeSH terms
- Antiparkinson Agents, Carbidopa, Catechols, Delivery of Health Care, Humans, Levodopa, Nitriles, Parkinson Disease, Patient Compliance, Retrospective Studies, Cohort Studies, Health Care Costs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Association between Adherence to Levodopa/Carbidopa/Entacapone Therapy and Healthcare Utilization and Costs among Patients with Parkinsonʼs Disease: A Retrospective Claims-Based Analysis. https://app.cochat.ai/papers/10.2165/11538970-000000000-00000
- The paper
- Delea, T. E., Thomas, S. K., & Hagiwara, M. (2011). The Association between Adherence to Levodopa/Carbidopa/Entacapone Therapy and Healthcare Utilization and Costs among Patients with Parkinsonʼs Disease: A Retrospective Claims-Based Analysis. CNS Drugs. https://doi.org/10.2165/11538970-000000000-00000
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.